The assessment of appropriate tumor cell lines amenable to anti-VEGF-B therapy was performed by flow cytometry following immunofluorescent staining of cell surface VEGFR-1 and VEGFR-2, or intracellular VEGF-B expression in breast carcinoma (MDA-MB-231 and DU4475, MCF-7) and colon carcinoma cell lines (COLO205, HT29, LIM1215, LIM1899, SW1222) (Figure 1B). This evidence concerns the gene KDR and neoplasm.